ASH 2020: Recombinant Factor VIII-Fc Fusion Protein With an Extended Half-Life Appears Safe and Effective in Previously Untreated Boys With Hemophilia A
Inhibitor development was within the expected range
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.